Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Heart and Circulatory Physiology
Adults with type 1 diabetes who used a GLP-1 receptor agonist or other incretin-based drug had lower risk for all-cause mortality, hospitalization and other clinical health outcomes than those not using a GLP-1, according to study data
Reddy's and Apotex) launched in Canadian pharmacies in May 2026, with seven additional submissions (including Sandoz and Teva Canada) still under Health Canada review
This pattern suggests Canadian approval for Retatrutide could occur around 2028-2029 if the US approval timeline holds at 2026-2027
US$ 22.39
US$ 22.02
US$ 28.75
